Enclosed please find herewith unaudited financial results for the first quarter ended June 30, 2026.

ALIVUS LIF E SCIENCES Evolve every day July 30, 2026 To, To, Dy. General Manager The Manager - Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub: Unaudited Financial Results for the First Quarter ended June 30, 2026 Pursuant to Regulations 30 and 33 of the SEBI (LODR), 2015, we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the First Quarter ended June 30, 2026. The said meeting of the Board commenced at 4.45 p.m. and concluded at 5.50 p.m. The copy of the said Results and Limited Review Report of the Auditor is enclosed herewith. These are also being made available on the website of the Company at www.alivus.com You are requested to take the same on record. Thanking You. Yours faithfully, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Company Secretary and Compliance Officer Encl.: As above Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Corporate Office Registered Office Technopolis Knowledge Park, A Wing, 4th Floor, Office No 401 to 407 Plot No 170-172, Chandramouli Industrial Estate Hanuman Nagar, Mahakali Caves Road, Andheri East, Mumbai 400 093 Mohol Bazarpeth; Solapur 413 213, India Maharashtra, India T: +91 22 6829 7979 I CIN: L74900PN2011PLC139963 IE: complianceofficer@alivus.com W: www.alivus.com ALIVUS LIFE SCIENCES Evolve every day STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30thJUNE 2026 (~ in Million, unless otherwise stated) Quarter ended Year ended Particulars June 30, 2026 March 31, 2026 June 30, 2025 March 31, 2026 (Unaudited) (Refer No 7) (Unaudited) Audited I Income Revenue from operations 6,404.14 6,891.17 6,018.46 25,518.32 Other income 224.01 227.78 89.85 604.11 Total income 6,628.15 7,118.95 6,108.31 26,122.43 II Expenses Cost of materials consumed 2,531.46 2,287.07 2,689.75 10,630.05 Changes in inventories of finished goods 18.98 421.39 14.10 35.63 and work-in-progress Employee benefits expense 682.45 781.22 615.77 2,724.69 Finance costs 13.07 13.09 12.51 53.72 Depreciation and amortisation expenses 205.85 202.00 170.64 753.57 Other expenses 1,054.11 1,256.19 975.73 4,155.11 Total expenses 4,505.92 4,960.96 4,478.50 18,352.77 111 Profit before exceptional items and 2,122.23 2,157.99 1,629.81 7,769.66 tax (1-11) IV Exceptional items (refer note 6) Statutory impact of new labour codes - - - 256.57 V Profit before tax (Ill-IV) 2,122.23 2,157.99 1,629.81 7,513.09 VI Tax expenses Current tax 502.74 510.89 389.36 1,838.92 Deferred tax 18.73 20.49 25.10 29.34 Total tax expenses 521.47 531.38 414.46 1,868.26 VII Net profit for the period / year (V-VI) 1,600.76 1,626.61 1,215.35 5,644.83 VIII Other comprehensive income Items that will not be reclassified to profit or loss (a) Re-measurement of the post- 4.12 17.12 (4.00) 16.47 employment benefit obligation (b) Income tax relating to the above (1.04) (4.30) 0.96 (4.23) Total other comprehensive income I 3.08 12.82 (3.04) 12.24 (loss), after tax IX Total comprehensive income for the 1,603.84 1,639.43 1,212.31 5,657.07 period / year (Vll+VIII) X Paid up equity share capital, equity 245.48 245.47 245.26 245.47 shares of~ 2/-each XI Other equity excluding revaluation 33,075.85 reserve XII Earnings per equity share (Face value off 2/-each) (not annualised except for the year ended 31st March) (a) Basic (in ~) 13.04 13.23 9.91 45.99 (b) Diluted (in~) 13.01 13.22 9.88 45.90 See accompanymg notes to the fmanctaf results Alivus Life Sciences Limited (formerly Gle ited) Corporate Office Registered Office Technopolis Knowledge Park, A Wing, 4th Floor, 0 Plot No 170-172, Chandramouli Industrial Esta,~ =:::::::;j(' Hanuman Nagar, Mahakali Caves Road, Andheri East, um a1 Moho! Bazarpeth, Solapur 413 213, India Maharashtra, India I I I T: +91 22 6829 7979 CIN: L74900PN2011PLC139963 E: complianceofficer@alivus.com W: www.alivus.com ALIVUS LIF E SCIE NC ES Evolve every day Notes: 1. The above financial results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued from time to time. 2. The above financial results were reviewed and recommended by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on July 30, 2026. The results for the quarter ended June 30, 2026 have been subjected to limited review by the statutory auditors of the company, who have expressed an unmodified review conclusion on the said results. 3. The Company has identified only one segment i.e. Active Pharmaceutical Ingredient (API) as reporting segment based on the information reviewed by Chief Operating Decision Maker (CODM). 4. As at June 30, 2026, pursuant to Employee Stock Option Plan 2021, 542,531 options were outstanding, which upon exercise are convertible into equivalent number of equity share. 5. The paid-up equity share capital stands increased to Rs. 245.48 million (122,739,448 equity shares of face value Rs. 2 each) upon allotment of 3,100 equity shares of Rs. 2 each pursuant to "Employee Stock Option Scheme, 2021" during the quarter ended June 30, 2026. 6. Exceptional items for the year ended March 31, 2026 includes the incremental effect on application of new labour codes comprising gratuity amounting to Rs. 170.02 million and compensated absences amounting to Rs. 86.55 million, recognised as past service cost. 7. The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited year to date figures upto the third quarter of the relevant financial year. For Alivus Life Sciences Limited {formerly Glenmark Life Sciences Limited) Yasir Rawjee Managing Director & CEO DIN: 01965174 Mumbai, July 30, 2026 Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Corporate Office Registered Office Technopolis Knowledge Park, A Wing, 4th Floor, Office No 401 to 407 Plot No 170-172, Chandramouli Industrial Estate Hanuman Nagar, Mahakali Caves Road, Andheri East, Mumbai 400 093 Mohol Bazarpeth, Solapur 413 213, India Maharashtra, India I I I T: +9122 6829 7979 CIN: L74900PN2011PLC139963 E: complianceofficer@alivus.com W: www.alivus.com Walker Chandiok &_Co LLP Walker Chandiok & Co LLP 42nd Floor, Building Commerz 111, International Business Park, Oberoi Garden City, Off Western Express Highway, Goregaon (East), Mumbai-400063 T +91 22 6626 2699 Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) 1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) ('the Company') for the quarter ended 30 June 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Com [Showing first 8,000 characters — download PDF for full document]